Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2016

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2016-12-23: Form 6-K; Period of report 2016-12-23; Description AZ COMPLETES SALE OF ANTIBIOTICS BUSINESS; Document a6592s.htm.
  • 2016-12-16: Form 6-K; Period of report 2016-12-16; Description DIRECTOR/PDMR SHAREHOLDING; Document a0979s.htm.
  • 2016-12-09: Form 6-K; Period of report 2016-12-09; Description FDA ACCEPTS DURVALUMAB FOR BLA IN BLADDER CANCER; Document a4866r.htm.
  • 2016-12-06: Form 6-K; Period of report 2016-12-06; Description TAGRISSO DATA SHOWS SUPERIORITY OVER CHEMOTHERAPY; Document a0811r.htm.
FiledFormPeriod of reportDescriptionDocument
2016-12-236-K2016-12-23AZ COMPLETES SALE OF ANTIBIOTICS BUSINESSa6592s.htm
2016-12-166-K2016-12-16DIRECTOR/PDMR SHAREHOLDINGa0979s.htm
2016-12-096-K2016-12-09FDA ACCEPTS DURVALUMAB FOR BLA IN BLADDER CANCERa4866r.htm
2016-12-066-K2016-12-06TAGRISSO DATA SHOWS SUPERIORITY OVER CHEMOTHERAPYa0811r.htm
2016-12-056-K2016-12-05AZ COMPLETES AGREEMENT FOR RHINOCORT AQUA RIGHTSa8911q.htm
2016-12-016-K2016-12-01BLOCK LISTING INTERIM REVIEWa7410q.htm
2016-12-016-K2016-12-01TOTAL VOTING RIGHTSa7328q.htm
2016-11-226-K2016-11-22AZ HEAD AND NECK CANCER TRIALS RESUME ENROLMENTa7949p.htm
2016-11-176-K2016-11-17AZ OUT-LICENSING DEAL WITH ALLERGAN COMPLETEDa3960p.htm
2016-11-106-K2016-11-10YEAR-TO-DATE AND Q3 2016 RESULTSa123.htm
2016-11-096-K2016-11-09DIRECTORATE CHANGEa6592o.htm
2016-11-016-K2016-11-01DEALING BY PERSON CLOSELY ASSOCIATEDa0248o.htm
2016-11-016-K2016-11-01TOTAL VOTING RIGHTSa0233o.htm
2016-10-316-K2016-10-31AZ COMPLETES US ARALEZ AGREEMENT FOR TOPROL-XLa8873n.htm
2016-10-276-K2016-10-27ASTRAZENECA HEAD AND NECK CANCER TRIALSa6677n.htm
2016-10-266-K2016-10-26POSITIVE RESULTS IN ASTRAZENECA LYNPARZA TRIALa4488n.htm
2016-10-186-K2016-10-18FDA ACCEPTS FOR REVIEW ZS-9 NDA FOR HYPERKALAEMIAa7697m.htm
2016-10-076-K2016-10-07AZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE USa9507l.htm
2016-10-046-K2016-10-04AZ AGREEMENT WITH ARALEZ FOR TOPROL-XL IN USa5979l.htm
2016-10-046-K2016-10-04ASTRAZENECA REPORTS TOP-LINE EUCLID RESULTS IN PADa5699l.htm
2016-10-036-K2016-10-03TOTAL VOTING RIGHTSa5271l.htm
2016-10-036-K2016-10-03MEDIMMUNE OUT-LICENSES MEDICINE TO ALLERGANa4518l.htm
2016-09-286-K2016-09-28CHANGE TO ASTRAZENECA BOARD OF DIRECTORSa9775k.htm
2016-09-266-K2016-09-26DIRECTOR/PDMR SHAREHOLDINGa8432k.htm
2016-09-226-K2016-09-22DIRECTOR DECLARATIONa5667k.htm
2016-09-016-K2016-09-01TOTAL VOTING RIGHTSa7186i.htm
2016-09-016-K2016-09-01ASTRAZENECA COMPLETES ASPEN AGREEMENTa6216i.htm
2016-08-246-K2016-08-24AZ TO SELL ANTIBIOTICS BUSINESS TO PFIZERa9866h.htm
2016-08-186-K2016-08-18DIRECTOR DECLARATIONa5617h.htm
2016-08-166-K2016-08-16ASTRAZENECA COMPLETES AGREEMENT WITH LEO PHARMAa2612h.htm
2016-08-106-K2016-08-10ASTRAZENECA ANNOUNCES INVESTMENT IN MODERNAa8449g.htm
2016-08-096-K2016-08-09ASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIALa5991g.htm
2016-08-016-K2016-08-01TOTAL VOTING RIGHTSa8565f.htm
2016-08-016-K2016-08-01DIRECTOR/PDMR SHAREHOLDINGa8259f.htm
2016-07-286-K2016-07-28AZN: H1 2016 RESULTSa4585f.htm
2016-07-276-K2016-07-27NOTICE OF RESULTSa3177f.htm
2016-07-196-K2016-07-19QTERN (SAXA/DAPA) EU APPROVED FOR TYPE-2 DIABETESa6212e.htm
2016-07-186-K2016-07-18TAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIALa3970e.htm
2016-07-016-K2016-07-01TOTAL VOTING RIGHTSazn201607016k2.htm
2016-07-016-K2016-07-01AZ ENTERS LICENSING AGREEMENTS WITH LEO PHARMAazn201607016k.htm
2016-06-286-K2016-06-28ZAVICEFTA APPROVED IN EUazn201606286k.htm
2016-06-236-K2016-06-23ASTRAZENECA UPDATES ON FLUMIST VACCINE IN THE USazn201606236k.htm
2016-06-146-K2016-06-14DIRECTOR/PDMR SHAREHOLDINGazn201606146k.htm
2016-06-096-K2016-06-09AZ AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIOazn201606096k.htm
2016-06-036-K2016-06-03AZ COMPLETES US LICENSING AGREEMENT WITH IRONWOODazn201606036k.htm
2016-06-026-K2016-06-02AZ LICENSES ZURAMPIC TO GR?NENTHAL GMBHazn201606026k.htm
2016-06-016-K2016-06-01BLOCK LISTING INTERIM REVIEWazn201606016k2.htm
2016-06-016-K2016-06-01TOTAL VOTING RIGHTSazn201606016k.htm
2016-05-276-K2016-05-27POSITIVE CHMP OPINION IN EU FOR SAXA/DAPAazn201605276k3.htm
2016-05-276-K2016-05-27POSITIVE RESULTS FROM ASTRAZENECA FASLODEX TRIALazn201605276k2.htm
2016-05-276-K2016-05-27ASTRAZENECA RECEIVES CRL FROM US FDA FOR ZS-9azn201605276k.htm
2016-05-236-K2016-05-23DIRECTOR/PDMR SHAREHOLDINGazn201605236k.htm
2016-05-186-K2016-05-18TOP-LINE RESULTS FROM LYNPARZA GOLD TRIALazn201605186k.htm
2016-05-176-K2016-05-17POSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMAazn201605176k.htm
2016-05-126-K2016-05-12SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN USazn201605126k.htm
2016-05-116-K2016-05-11PUBLICATION OF FINAL TERMSazn201605116k.htm
2016-05-096-K2016-05-09LAUNCH AND PRICING OF EUR2.2BN BOND ISSUESazn201605096k.htm
2016-05-056-K2016-05-05PUBLICATION OF A PROSPECTUSazn201605056k.htm
2016-05-036-K2016-05-03TOTAL VOTING RIGHTSazn201605036k2.htm
2016-05-036-K2016-05-03AZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORYazn201605036k.htm
2016-05-036-K2016-05-03ASTRAZENECA COMPLETES DIVESTMENT OF IMDURazn201605036k1.htm
2016-04-296-K2016-04-29RESULT OF AGMazn201604286k3.htm
2016-04-296-K2016-04-29POSITIVE CHMP OPINION FOR CAZ AVIazn201604296k2.htm
2016-04-296-K2016-04-29AZN: 1ST QUARTER RESULTSazn201604296k.htm
2016-04-286-K2016-04-28NOTICE OF RESULTSazn201604276k.htm
2016-04-266-K2016-04-26AZ ENTERS US LICENSING AGREEMENT WITH IRONWOODazn201604266k2.htm
2016-04-266-K2016-04-26BEVESPI AEROSPHERE APPROVED BY US FDA FOR COPDazn201604266k.htm
2016-04-086-K2016-04-08AZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIALazn201604086k.htm
2016-04-016-K2016-04-01TOTAL VOTING RIGHTSazn201604016k.htm
2016-03-296-K2016-03-29TAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTSazn201603296k.htm
2016-03-246-K2016-03-24DIRECTOR/PDMR SHAREHOLDINGazn201603246k.htm
2016-03-236-K2016-03-23AZ REPORTS RESULTS FROM BRILINTA STROKE TRIALazn201603236k.htm
2016-03-186-K2016-03-186-Kd162922d6k.htm
2016-03-186-K2016-03-18NOTICE OF AGMazn201603186k.htm
2016-03-086-K2016-03-08FILING OF FORM 20-F WITH SECazn201603086k1.htm
2016-03-086-K2016-03-08ANNUAL FINANCIAL REPORTazn201603086k.htm
2016-03-016-K2016-03-01TOTAL VOTING RIGHTSazn201603016k.htm
2016-02-296-K2016-02-29AZ REPORTS TOP-LINE RESULT OF TREMELIMUMAB TRIALazn201602296k2.htm
2016-02-296-K2016-02-29AZ ENTERS LICENSING AGREEMENT WITH CMS FOR PLENDILazn201602296k.htm
2016-02-266-K2016-02-26DIRECTOR/PDMR SHAREHOLDINGazn201602266k.htm
2016-02-256-K2016-02-25ACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDEDazn201602256k.htm
2016-02-196-K2016-02-19BRILIQUE APPROVED IN EU FOR HEART ATTACK PATIENTSazn201602196k2.htm
2016-02-196-K2016-02-19ZURAMPIC APPROVED IN EU FOR GOUT PATIENTSazn201602196k.htm
2016-02-166-K2016-02-16NEW EXTERNAL BOARD APPOINTMENTazn201602166k.htm
2016-02-046-K2016-02-04ASTRAZENECA FULL-YEAR AND Q4 2015 RESULTSazn201602046k.htm
2016-02-036-K2016-02-03TAGRISSO APPROVED IN EU FOR CANCER PATIENTSazn201502036k.htm
2016-02-036-K2016-02-03NOTICE OF RESULTSazn201602026k1.htm
2016-02-026-K2016-02-02AZ COMPLETES TRANSACTION WITH ACERTA PHARMAazn201602026k.htm
2016-02-016-K2016-02-01TOTAL VOTING RIGHTSazn201602016k.htm
2016-01-286-K2016-01-28LYNPARZA GRANTED BTD IN US FOR PROSTATE CANCERazn201601286k.htm
2016-01-046-K2016-01-04DIRECTOR/PDMR SHAREHOLDINGazn201601046k3.htm
2016-01-046-K2016-01-04DIRECTOR/PDMR SHAREHOLDINGazn201601046k2.htm
2016-01-046-K2016-01-04TOTAL VOTING RIGHTSazn201601046k.htm
Advertisement